These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38219628)

  • 21. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
    Korninger C; Matsuo O; Suy R; Stassen JM; Collen D
    J Clin Invest; 1982 Mar; 69(3):573-80. PubMed ID: 7199539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remaining perspectives of mutant and chimeric plasminogen activators.
    Lijnen HR; Collen D
    Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Position and developmental trends in fibrinolytic therapy].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):6-17. PubMed ID: 2427416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis.
    Zhang N; Li C; Zhou D; Ding C; Jin Y; Tian Q; Meng X; Pu K; Zhu Y
    Acta Biomater; 2018 Apr; 70():227-236. PubMed ID: 29412186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models.
    Xu J; Zhang Y; Xu J; Liu G; Di C; Zhao X; Li X; Li Y; Pang N; Yang C; Li Y; Li B; Lu Z; Wang M; Dai K; Yan R; Li S; Nie G
    Adv Mater; 2020 Jan; 32(4):e1905145. PubMed ID: 31788896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
    Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
    Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecularly self-fueled nano-penetrator for nonpharmaceutical treatment of thrombosis and ischemic stroke.
    Zhang H; Zhao Z; Sun S; Zhang S; Wang Y; Zhang X; Sun J; He Z; Zhang S; Luo C
    Nat Commun; 2023 Jan; 14(1):255. PubMed ID: 36650139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomimetic Nanoplatelets to Target Delivery Hirudin for Site-Specific Photothermal/Photodynamic Thrombolysis and Preventing Venous Thrombus Formation.
    Li S; Zhang K; Ma Z; Zhang W; Song Z; Wang W; Han H
    Small; 2022 Dec; 18(51):e2203184. PubMed ID: 36344452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poly-
    Chen S; Liang M; Wu C; Zhang X; Wang Y; Zhao M
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous Targeted Microbubbles Carrying Urokinase versus Urokinase Alone in Acute Peripheral Arterial Thrombosis in a Porcine Model.
    Nederhoed JH; Ebben HP; Slikkerveer J; Hoksbergen AWJ; Kamp O; Tangelder GJ; Wisselink W; Musters RJP; Yeung KK
    Ann Vasc Surg; 2017 Oct; 44():400-407. PubMed ID: 28546045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.
    Maksimenko AV; Tischenko EG
    J Thromb Thrombolysis; 1999 Jun; 7(3):307-12. PubMed ID: 10373713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic Analysis of Combined Thrombolysis Using Ultrasound and Different Fibrinolytic Drugs in an in Vitro Clot Model of Intracerebral Hemorrhage.
    Masomi-Bornwasser J; Fabrig O; Krenzlin H; König J; Tanyildizi Y; Kempski O; Ringel F; Keric N
    Ultrasound Med Biol; 2021 May; 47(5):1334-1342. PubMed ID: 33549380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A microthrombus-driven fixed-point cleaved nanosystem for preventing post-thrombolysis recurrence via inhibiting ferroptosis.
    Sun M; Liu C; Liu J; Wen J; Hao T; Chen D; Shen Y
    J Control Release; 2024 Mar; 367():587-603. PubMed ID: 38309306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of thrombolytic agents to treat neonatal thrombosis in clinical practice.
    Leong R; Patel J; Samji N; Paes BA; Chan AKC; Petropoulos JA; Bhatt MD;
    Blood Coagul Fibrinolysis; 2022 Jun; 33(4):193-200. PubMed ID: 35285449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction.
    Anand S; Diamond SL
    Circulation; 1996 Aug; 94(4):763-74. PubMed ID: 8772700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
    Wang YX; da Cunha V; Vincelette J; Zhao L; Nagashima M; Kawai K; Yuan S; Emayan K; Islam I; Hosoya J; Sullivan ME; Dole WP; Morser J; Buckman BO; Vergona R
    Thromb Haemost; 2007 Jan; 97(1):54-61. PubMed ID: 17200771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.
    Ma H; Jiang Z; Xu J; Liu J; Guo ZN
    Drug Deliv; 2021 Dec; 28(1):357-371. PubMed ID: 33517820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.